<DOC>
	<DOC>NCT02715258</DOC>
	<brief_summary>The purpose of this study is to investigate the effect of bexagliflozin in lowering hemoglobin A1c (HbA1c) levels in patients with type 2 diabetes mellitus (T2DM).</brief_summary>
	<brief_title>Safety and Efficacy of Bexagliflozin as Monotherapy in Patients With Type 2 Diabetes</brief_title>
	<detailed_description>Approximately 210 subjects with inadequately controlled T2DM will be recruited from US and Canada. Subjects will be randomly assigned to receive bexagliflozin tablets, 20 mg, or placebo in a ratio of 2:1 once daily for 24 weeks.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Subjects with T2DM Subjects who are not currently taking medication for diabetes or who are taking only one oral medication for diabetes Subjects whose doses of blood pressure or cholesterol medications (if applicable) have not changed for at least 30 days Diagnosis of type 1 diabetes mellitus or maturityonset/diabetes of the young Current use of injected therapy for treatment of diabetes (insulin or GLP1 receptor agonist therapy) or thiazolidinedione class drugs History of genitourinary tract infections Evidence of abnormal liver function Myocardial infarction, stroke or hospitalization for heart failure within 3 months of screening Prior kidney transplant or evidence of kidney problems Pregnant or nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>